Background SSc-ILD and IPF demonstrate significant morbidity and mortality. Predicting
disease progression is challenging in both diseases. Objectives We sought a serum …

Objective. To identify predictors of poor prognosis in patients with systemic sclerosis (SSc)
associated with interstitial lung disease (ILD). Methods. Fifty patients with early-stage SSc …

Objective. A single-centre retrospective longitudinal study to investigate the predictive value
of KL-6 serum levels for the outcome of interstitial lung fibrosis in a large systemic sclerosis …

The development of a progressive phenotype of interstitial lung disease (ILD) is still
unpredictable. Whereas tools to predict mortality in ILD exist, scores to predict disease …

Objective Interstitial lung disease (ILD) in systemic sclerosis (SS c) runs a highly variable
course, and prediction tools are highly desired. The aim of this study was to assess the …

Objective. Biomarkers of progression of interstitial lung disease (ILD) are needed to allow
early therapeutic intervention in patients with scleroderma-associated disease (SSc-ILD) …

Background Interstitial lung disease (ILD) is frequent complication of systemic sclerosis
(SSc) and mixed connective tissue disease (MCTD). The disease is heterogeneous, and its …

Background The clinical course of patients with systemic sclerosis-associated interstitial
lung disease (SSc-ILD) is highly variable. The Krebs von den Lungen-6 (KL-6) glycoprotein …

Disease progression (DP) is an important parameter for the prognosis of idiopathic
pulmonary fibrosis (IPF). This study aimed to evaluate the baseline serum biomarkers for …

The clinical significance of serial changes in serum biomarkers in patients with idiopathic
pulmonary fibrosis (IPF) remains to be established. This retrospective study was conducted …